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Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitors, are effective in lowering blood cholesterol as well 
as in primary and secondary prevention of cardiovascular 
events. Approximately 25 million people worldwide are tak-
ing statins.1–3 Statins are safe and effective in the majority of 
patients, but they are associated with muscle toxicity, which, 
although rare, can be serious and potentially life threatening.4,5 
The clinical spectrum of statin-induced myotoxicity varies 
greatly from asymptomatic elevations of creatine kinase (CK) 
without muscle pain, to muscle pain or weakness with raised CK 
levels, myositis with biopsy-proven muscle inflammation, and, 
finally, rhabdomyolysis with muscle symptoms, high CK, and 
potential for acute kidney injury (Table 1).6,7 Whether statins 
cause muscle pain in the absence of CK changes remains con-
troversial. Although milder forms of myotoxicity tend to be self-
limiting and disappear after cessation of therapy, they can lead 
to poor quality of life, poor drug compliance, and, consequently, 
the failure to prevent cardiovascular events.
Because statin-induced myotoxicity is uncommon, it is neces-
sary to pool and analyze data from various sources, including 
multicenter clinical trials and observational studies, to study 
genetic etiology. In addition, electronic medical records linked 
to biological repositories or to individual patients have been 
useful in identifying and recruiting patients with drug-induced 
toxicities.6,8–12 The Phenotype Standardization Project was 
started a few years ago to facilitate such multicenter research 
collaborations on various types of serious adverse drug reac-
tions (ADRs). Phenotype consensus papers on drug-induced 
liver injury, skin injury, and torsade de pointes have been pub-
lished by multidisciplinary groups of international experts.13–15 
The aim of this article is to provide consensus definitions for 
statin-induced myotoxicity phenotypes, to facilitate cross-study 
comparisons from the existing cohorts, to aid in the recruit-
ment of retrospective and newly diagnosed patients with 
 statin-induced muscle damage, and to define the phenotype 
for genomic data analyses.
We convened an international expert workshop on statin-
induced myotoxicity in December 2013 in Liverpool, UK, to 
agree on definitions and a minimum set of criteria to help in 
identification and recruitment. We report on the deliberations of 
this workshop: first, we summarize evidence of the clinical and 
biochemical phenotypes that have been reported, and second, 
we report on our suggested standardization of the terminology 
and phenotypes of statin-induced muscle toxicity.
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Statins are widely used lipid-lowering drugs that are effective in reducing cardiovascular disease risk. Although they are 
generally well tolerated, they can cause muscle toxicity, which can lead to severe rhabdomyolysis. Research in this area 
has been hampered to some extent by the lack of standardized nomenclature and phenotypic definitions. We have used 
numerical and descriptive classifications and developed an algorithm to define statin-related myotoxicity phenotypes, 
including myalgia, myopathy, rhabdomyolysis, and necrotizing autoimmune myopathy.
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CONSENSUS PROCESS
The PREDICTION-ADR consortium, funded by the EU 
Seventh Framework Programme, organized a joint meeting on 
10 December 2013 in Liverpool with a multidisciplinary team 
of experts on statin-related myopathy and angiotensin convert-
ing enzyme-inhibitor angioedema. An international team with 
known expertise in the area was assembled by invitation. The 
group comprised clinical and basic pharmacologists, internists, 
rheumatology and myopathy experts, immunology and clinical 
chemistry scientists, allergists, regulatory agency representa-
tives, and managers of electronic medical record databases.
A draft manuscript circulated before the meeting contained a 
brief literature review on statin-related myopathy and a descrip-
tion of main phenotypes. The expert group was asked to con-
sider the minimum set of criteria for patient recruitment. An 
introductory talk was given to start the discussions. In addition, 
an algorithm was designed to aid standardization of nomencla-
ture and phenotypes, and recommendations were made about 
the types of data to be collected from each patient (Figure 1). 
After the meeting, the revised manuscript comprising the cri-
teria (Table 1) and algorithm was approved by all contributors.
We did not discuss causality assessment formally, as the chal-
lenges of this task are common for many ADRs.16 They require 
establishing a temporal relationship, along with dechallenge and 
rechallenge information, and, particularly important for statin-
related myotoxicity, vigilant information on muscle injury from 
falls, trauma, or vigorous exercise. We also recommend inde-
pendent assessment of causality by an adjudication panel, using 
methodology that has been successfully applied to retrospective 
and prospective recruitment of patients with rare ADRs, includ-
ing severe drug-induced skin injury.15
INCIDENCE
The rate of statin-induced myotoxicity has been estimated from 
adverse event data in case series and randomized controlled 
 trials.17–24 However, estimating adverse events from randomized 
controlled trials may be challenging because (i) they are not 
usually powered to capture low-frequency ADRs; (ii) patients 
are exposed to drugs and monitored only for a short period of 
time when myotoxicity may not yet have developed; (iii) the diag-
nostic criteria for reaction events may vary across different trials; 
and (iv) they may have strict inclusion and exclusion criteria that 
may exclude some populations who are at higher risk of ADRs.
The risk of rhabdomyolysis among hospitalized patients receiv-
ing lipid-lowering drugs has recently been estimated in a real-
world clinical setting. Claims data from 9 million members of 
five US health plans were used to confirm 42 cases in >470,000 
patients exposed to lipid-lowering drugs. The risk of rhabdomy-
olysis for individuals on different statin preparations, including 
combination therapy, and the risk of comorbidities were estimated 
to be between 0.3 and 8.4 in 10,000 patient-years.25 The authors 
estimated that the risk in comparison with atorvastatin as a refer-
ence was significantly higher when statins were used in combina-
tion with cytochrome P450 (CYP)3A4 inhibitors (odds ratio: 7.1, 
95% confidence interval: 1.6–31.6) and for cerivastatin mono-
therapy (odds ratio: 4.7, 95% confidence interval: 1.1–21.1).25
DIAGNOSTIC CRITERIA
The diagnosis of statin-induced myotoxicity is based on medi-
cal history, clinical examination, and laboratory tests and can 
be confirmed by muscle biopsy (Supplementary Table S1 
online). Muscle biopsies can reveal muscle fiber necrosis, type 
II fiber atrophy, and increased lipid stores in muscle fibers or 
inflammation.26–29 In clinical practice, a pragmatic approach is 
adopted: discontinuation of the culprit drug and avoidance of 
its future use.30 Monitoring of statin therapy for muscle toxicity 
includes CK measurements, although routine laboratory testing 
is recommended only for symptomatic patients.31 The potential 
harm of introducing routine CK monitoring in all patients who 
take statins may outweigh the benefits from several perspec-
tives, including false-positive results with potentially ensuing 
invasive investigations, a psychological effect on patients that 
may result in reduction of statin use, and an increased cost to 
the health-care system. A recent study on patients’ perceptions 
Table 1 Statin-related myotoxicity phenotype classification
SRM classification Phenotype Incidence Definition Reference
SRM 0 CK elevation <4× ULN 1.5–26% No muscle symptoms Refs. 1,20,34,35,67
SRM 1 Myalgia, tolerable 190/100,000  
Patient-years; 0.3–33%
Muscle symptoms without CK elevation Refs. 1,19,21,50,68
SRM 2 Myalgia, intolerable 0.2–2/1,000 Muscle symptoms, CK <4× ULN, complete 
resolution on dechallenge
Ref. 20
SRM 3 Myopathy 5/100,000  
Patient-years
CK elevation >4× ULN <10× ULN ± muscle 
symptoms, complete resolution on dechallenge
Ref. 1
SRM 4 Severe myopathy 0.11% CK elevation >10× ULN <50× ULN, muscle 
symptoms, complete resolution on dechallenge
Refs. 20,69
SRM 5 Rhabdomyolysis 0.1–8.4/100,000 
Patient-years
CK elevation >10× ULN with evidence of renal 
impairment + muscle symptoms or CK >50× ULN
Refs. 4,6,25,44,45
SRM 6 Autoimmune-mediated 
necrotizing myositis
~2/million per year HMGCR antibodies, HMGCR expression in muscle 
biopsy, incomplete resolution on dechallenge
Refs. 51,70
Numeric classification was developed by an expert group; descriptive nomenclature was adapted from the recommendation of the American College of Cardiology/American 
Heart Association/National Heart, Lung, and Blood Institute Clinical Advisory Board.3,7
CK, creatine kinase; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; SRM, statin-related myotoxicity; ULN, upper limit of normal.
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of statin therapy has demonstrated reduced adherence to statin 
therapy in those concerned about ADRs.32,33
CLINICAL PRESENTATIONS OF STATIN-INDUCED MUSCLE 
TOXICITY
Statin-induced muscle toxicity can present in many different 
ways, but the recognized phenotypes and degrees of severity 
are classified into seven different categories, as represented in 
Table 1 (statin-related myotoxicity (SRM) 0–SRM 6).
Muscle symptoms
Statin-induced muscle toxicity may present with a wide variety 
of symptoms, including fatigue, muscle pain, muscle weakness, 
muscle tenderness, and cramps. These symptoms are usually 
proximal and symmetrical but may be generalized. They can be 
aggravated by vigorous exercise and sometimes by addition of a 
new medication.2 Pain tolerance varies greatly in different indi-
viduals, and many studies have relied on self-reporting of muscle 
symptoms. If patients can tolerate mild muscle pain, statins are 
not usually discontinued (SRM 1, Table 1).
Plasma CK elevation
Asymptomatic serum CK elevations (SRM 0) and muscle pain 
without an increase in CK (SRM 1) have been the two most 
commonly (occurring in up to 33% of patients) described 
features of statin-induced toxicity.20,34,35 With the increasing 
use of electronic medical records, it may be possible to use CK 
elevations to identify patients with statin myotoxicity. However, 
because the use of CK as a screening test for muscle injury is not 
recommended, the identification of an isolated CK elevation in 
an electronic (or paper-based) record may indicate suspicion 
of the clinician of muscle  toxicity, even if symptoms are vari-
ably recorded. CK levels are often used as a crude estimate of 
severity, but the correlation between muscle symptoms and CK 
levels is imperfect, and the clinical interpretation of CK levels 
is complex.36 There is considerable variability in the inclusion 
criteria and CK levels in the literature, particularly in genetic 
susceptibility studies. Some authors investigate patients with 
self-reported myalgia and CK levels from 1 to 3× the upper limit 
of normal (ULN) (SRM 2), whereas others apply more stringent 
criteria with CK elevations >4× (ref. 1) (SRM 3) or >10× the 
ULN (SRM 4) for myopathy and ≥50× the ULN for rhabdo-
myolysis (SRM 5),9,35,37–42 which are the criteria used in some 
recent industry-funded studies. To prevent inclusion of patients 
with CK elevations from causes other than statin myotoxicity, 
we have adopted the >4× the ULN for myopathy (SRM 3) and 
>10× the ULN for severe myopathy (SRM 4). Although these 
cutoff points have been commonly used in clinical trials and in 
several guidelines, they are somewhat arbitrary. However, future 
analyses based on these cutoff points (<4× the ULN, 4–10× the 
ULN, and >10× the ULN) will help in defining the sensitivity 
and specificity of different genetic markers, and provide a first 
step in future refinement of cutoff levels. Some investigators have 
also used alanine aminotransferase elevation to identify mus-
cle injury;35 this may be of use when measured in combination 
with CK. Isolated elevation of alanine aminotransferase, in the 
Figure 1  Algorithm for defining the type of statin-related myotoxicity. New nomenclature was introduced to reflect the phenotype classification and severity 
(SRM 0 to SRM 6) of statin-related toxicity. CK, creatine kinase; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; LLD, lipid-lowering drug; SRM, statin-
related myotoxicity; ULN, upper limit of normal.
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absence of an increase in CK levels, should raise the suspicion of 
liver injury, which can also rarely occur with statins.43
Rhabdomyolysis
Rhabdomyolysis (SRM 5), the most serious ADR associated 
with statins,4,6,25,44,45 is characterized by muscle  necrosis, 
release of myoglobin into the bloodstream, and sometimes 
acute renal failure.4,6,26,45,46 Muscle symptoms are accom-
panied by marked CK elevation, typically greater than 50× 
the ULN. Pigment nephropathy with brown urine is typically 
evident due to myoglobinuria and is consistent with serum 
creatinine elevation.7
HMGCR autoantibodies
A number of studies (e.g., ref.46) have reported the occur-
rence of an autoimmune-mediated necrotizing myopa-
thy (SRM 6) after statin exposure, with symptoms that 
continued after drug withdrawal. Serum autoantibodies 
against 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
(HMGCR), the pharmacological target of statins, have been 
reported in patients with statin-induced autoimmune myo-
pathy.47 Muscle biopsies can also be diagnostically useful for 
the detection of HMGCR expression on the cell surface of 
regenerating muscle fibers.47 In 51 patients with self-lim-
ited statin intolerance, anti-HMGCR antibodies were not 
observed in a single individual.48 This suggests that self-
limited statin myopathy has a distinct biological mechanism 
from  statin-induced autoimmune myopathy. In addition, 
atorvastatin and simvastatin promote a proinflammatory 
or Th1 response in activated peripheral blood mononuclear 
cells by increasing the number of interferon-γ-secreting T 
cells.49 It should be noted, however, that many autoimmune 
myopathy cases are likely to be excluded from studies because 
withdrawal of the statins does not alleviate symptoms and 
Table 2 Reported risk factors for developing statin-induced myopathy
Risk factor Description Reference
Patient factors
  Advanced age >80 years) Ref. 7
  Female gender
Ref. 42
   Low body mass 
index
  Comorbidities Untreated hypothyroidism Ref. 50, Supplementary 
refs. 71 and 72
Low vitamin D level Supplementary ref. 73 
online
Chronic renal insufficiency (GFR 60 ml/min), especially when associated with diabetes Ref. 7,25
Infection, liver impairment, hypertension Ref. 25
Alcohol abuse Ref. 7
  Physical exercise Supplementary refs. 
74–76
  Surgery The American Heart Association recommends temporary cessation of statins before major surgery Ref. 7
   History of statin 
myopathy
Personal or family history of statin myopathy Ref. 50
Drug factors
  Higher statin dose Increased frequency of myopathy Supplementary refs. 77 
and 78
  Interacting drugsa CYP3A4 enzyme inhibitors (particularly important for CYP3A4 substrates simvastatin, lovastatin, 
and atorvastatin): diltiazem, verapamil, clarithromycin, telithromycin, erythromycin, itraconazole, 
cyclosporine, protease inhibitors (ritonavir, indinavir, and saquinavir), amiodarone, and fusidic acid
Refs. 59–62, 
Supplementary refs. 
79–81
CYP2C9 enzyme inhibitors (with effects on fluvastatin, a CYP2C9 substrate): omeprazole  
and fluconazole
Supplementary refs. 
82–84
OATP1B1 inhibition (with effects on simvastatin, pravastatin, lovastatin, and rosuvastatin):  
gemfibrozilb
Refs. 53–57 
Supplementary refs. 85 
and 86
Diet-related 
interactions
Grapefruit juice (>200 ml daily) increases levels of simvastatin, atorvastatin, and lovastatin
Supplementary refs. 71–87 are provided with Supplementary Table S1 online.
CYP, cytochrome P450; GFR, glomerular filtration rate; OATP, organic anion-transporting polypeptide.
aOnly a selection of drug interactions with statins has been presented. Readers should refer to more extensive reviews for a fuller list of interacting drugs (Kellick et al., 
2014 (Supplementary ref. 87), http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/DrugSafetyUpdatesearchresults/index.htm, and http://pharmacistsletter.
therapeuticresearch.com/pl/ArticleDD.aspx?nidchk=1&cs=&s=PL&pt=2&fpt=31&dd=280606&pb=PL&cat=4803&segment=4421&AspxAutoDetectCookieSupport=1).bThe 
main mechanism of the interaction is mentioned in the table, but it is important to note that in some cases there may be multiple mechanisms. For example, with gemfibrozil, in 
addition to OATP1B1 inhibition, CYP2C8 and UGT1 inhibition may also contribute. UGT, uridine diphosphate glucuronyltransferase.
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thus statins may be discounted as the causal agents for myo-
pathy pathogenesis.
TIME TO ONSET
In the PRIMO (Prediction of Muscular Risk in Observational 
Conditions) study, the median time to onset in the 832 of 7,924 
patients who developed muscular symptoms was one month 
after statin initiation.50 A study of 45 patients reported a mean 
duration of statin therapy before myopathic symptoms of 6.3 
months, with a maximum of 9.8 months.19
A large study, using a case-crossover design to determine 
statin myotoxicity in two primary-care databases comprising 
93,831 patients, suggested that most cases occur within the 
first 12 weeks of statin exposure.21 The authors recommended 
a 26-week cutoff to enable fewer misclassifications of exposed 
cases.21 A 26-week cutoff seems sensible for those patients 
who have been on a stable dose of statin monotherapy; how-
ever, this may need to be extended. It is important to note 
that some patients can develop statin myotoxicity either after 
a statin dose increase or after the concomitant administration 
of an interacting drug, which may occur anytime during the 
life cycle of statin use. Furthermore, autoimmune myopathy 
may take longer to develop, with a time to onset as long as 
3 years.51
RISK FACTORS
Concomitant medications
Fibrates. A significant body of evidence suggests an increased 
risk of statin myopathy, particularly rhabdomyolysis, in patients 
taking statins in combination with fibrates.4 Analysis of the 
US Food and Drug Administration Adverse Event Reporting 
System between 1998 and 2002 was used to determine report-
ing rates for rhabdomyolysis in patients taking fenofibrate and 
gemfibrozil in combination with statins.52 Gemfibrozil, a fibric 
acid derivative, increases systemic exposure to active simvasta-
tin acid by inhibiting both glucuronidation and organic anion-
transporting polypeptide (OATP)1B1 transporter–mediated 
uptake into the liver.53,54
Overall rates of rhabdomyolysis for any statin medication 
users coprescribed fenofibrate or gemfibrozil were 4.5 and 8.7 
per million prescriptions, respectively. When stratified to those 
patients receiving cerivastatin only, the rates increased to 140 
and 4,600 per million prescriptions with fenofibrate/cerivastatin 
and gemfibrozil/cerivastatin combination therapy, respectively.52 
Although the effect of fibrate coadministration on statin bio-
availability exists for the majority of statins,53,55–57 the increase 
in myopathy risk is especially pronounced with cerivastatin.5,58 
Although cerivastatin was withdrawn in 2001, the identification 
of predisposing pharmacogenomics factors may still be of use 
for elucidating predisposing factors of muscle toxicity with the 
statins more commonly used nowadays.
CYP3A4 inhibition. CYP3A4 inhibitors such as azole antifun-
gals, protease inhibitors, amiodarone, cyclosporine, calcium 
channel blockers, and macrolide antibiotics, to name a few, 
increase risk of myopathy for statins that undergo CYP3A4 
metabolism (simvastatin, atorvastatin, and lovastatin).59–62 In 
addition, some foods such as grapefruit juice, which contains 
furanocoumarins, irreversibly inhibit CYP3A4 in the gut. The 
effect is reduced gut wall metabolism of statins (particularly 
 simvastatin) and increased systemic exposure, which can lead 
to adverse effects.60,63
Comorbidities
A list of comorbidities that are associated with an increased risk 
of developing statin-related myotoxicity is shown in Table 2. 
They include hypothyroidism, chronic renal insufficiency, infec-
tion, impaired liver function, hypertension, physical exertion, 
and diabetes.
Exercise
It is commonly believed that vigorous exercise increases the risk 
of statin-induced myopathy. Indeed, it is thought that myopathic 
symptoms may occur in 25% of statin users who exercise, as 
compared with a population incidence estimated at 1–5% for 
those who exercise but do not take statins.64 In professional 
athletes, it is estimated that as many as 75% of those taking 
statins may develop muscular symptoms;65 however, this may 
be overestimated.
CONCLUSIONS
Given the high prevalence of statin use worldwide and their sig-
nificance in the prevention of cardiovascular and cerebrovascu-
lar disease, extensive research on the prediction and prevention 
of serious adverse effects such as statin-related myotoxicity is 
justified. Improved patient tolerability and adherence to statins 
is crucial because it reduces the incidence and the cost to any 
health-care system of treating cardiovascular disease. Large 
prospective studies of patient cohorts treated with statins are 
required to identify new genetic susceptibility biomarkers for 
statin-related myotoxicity that could be implemented into 
clinical practice. To date, one of the problems in comparing 
the results of observational studies on statin myotoxicity has 
been the lack of phenotype classification and standardization of 
nomenclature. In addition, given the rarity of the most severe 
phenotypes, a small sample size of several studies has hampered 
genetic biomarker discovery.
We have adapted a previously described consensus approach15 
to define phenotypic criteria that can be used in an effort to 
standardize statin-related myotoxicity phenotypes using the 
numerical and descriptive nomenclature given in Table 1. Our 
standardization was based on expert opinion from a multidis-
ciplinary group and the literature. The following are key criteria 
to be used in the deep phenotyping of patients with suspected 
statin-induced muscle injury:
•	 A CK level that is >4× the ULN in the presence or absence 
of clinical symptoms for the definition of myopathy. We 
have adopted the >4× the ULN level pragmatically, as we 
feel, based on the literature, that this cutoff provides the 
right balance in preventing inclusion of patients with CK 
elevation due to normal variation or other causes, while 
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simultaneously ensuring that we do not unnecessarily 
exclude valuable patients in studies investigating genetic 
factors predisposing to statin myotoxicity. A CK >10× the 
ULN should be categorized as rhabdomyolysis if accompa-
nied by renal impairment. The adoption of the classifica-
tion shown in Table 1 may help in more clearly defining 
the various phenotypes that are recruited in different 
studies. Papers reporting genetic factors predisposing to 
statin-induced muscle injury should show the effect size 
of the genetic polymorphism based on the degree of CK 
elevation, as has been done in recent studies.9,66
•	 Clinical symptoms need to be carefully recorded in the 
patients; these should include not only the muscle symp-
toms but also whether there is any involvement of the 
kidneys, which might indicate rhabdomyolysis. Causality 
assessment as to whether the statin was responsible should 
include details of the temporal relationship between 
onset of statin use and the occurrence of myotoxicity, the 
effect of dechallenge, and the effect of any rechallenge. 
Dechallenge may not always be successful, for example, 
in patients with autoimmune myopathy, and should not 
necessarily be used to exclude statins as etiological agents.
•	 Apart from CK, measurement of alanine aminotransferase, 
urine myoglobin levels (when clinically indicated), and 
renal function may be useful. In patients with a suspected 
autoimmune myopathy, the measurement of anti-HMGCR 
antibodies and muscle biopsy should be considered.
•	 Predisposing factors, including interacting drugs, comor-
bidities, and exercise, should be evaluated in all patients. 
Factors such as trauma that lead to muscle injury irrespec-
tive of statin use need to be excluded.
•	 The time to onset can be variable and can be delayed as 
long as 3 years in patients with autoimmune myopathy. 
However, in general, most cases of statin-induced myo-
toxicity occur within 6 months to 1 year of statin onset, 
an increase in the dose of the statin, or the concomitant 
administration of an interacting drug.
We have also developed an algorithm that will help assign 
phenotypes to individual patients based on clinical and bio-
chemical parameters (Figure 1).
We hope the criteria described in this article will help clini-
cians and researchers to categorize phenotypes in patients with 
statin-related myotoxicity in order to facilitate research in this 
area.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at 
http://www.nature.com/cpt
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